AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe 04:27:32 2024-07-02 am EDT 5-day change 1st Jan Change
12,243 GBX -0.50% Intraday chart for AstraZeneca PLC -2.61% +15.30%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone MT
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment MT
AstraZeneca's Imfinzi, Lynparza Combination Recommended for Approval in Europe as Endometrial Cancer Treatment MT
AstraZeneca applies to the EMA for a Covid antibody CF
AstraZeneca: CHMP recommends Imfinzi and Lynparza CF
Stocks called higher ahead of Thursday's election AN
AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application MT
AstraZeneca's Application for COVID-19 Prevention Drug Wins Accelerated Review in EU MT
AstraZeneca's COVID prevention drug application gets EU fast-track assessment RE
AstraZeneca Plc's Lynparza & Imfinzi Announces Positive CHMP in Endometrial CI
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug RE
European Equities Close Lower in Wednesday Trading MT
ASTRAZENECA : Deutsche Bank sticks Neutral ZD
AstraZeneca Says Tagrisso With Chemotherapy Approved in China MT
AstraZeneca: Tagrisso approved in China for NSCLC CF
AstraZeneca's Tagrisso plus chemo gets approval in China AN
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment RE
AstraZeneca Wins Chinese Regulatory Nod for Lung Cancer Combination Treatment MT
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla... Our Logo
AstraZeneca Says Imfinzi With Chemotherapy Improves Survival in Phase 3 Bladder Cancer Trial MT
AstraZeneca's Tagrisso Approved With Chemotherapy in Japan for Lung Cancer Treatment MT
AstraZeneca Says Phase 3 Imfinzi Trial in Early-Stage Lung Cancer Misses Primary Endpoint MT
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
155.5 USD
Average target price
174.4 USD
Spread / Average Target
+12.16%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application